Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups.

The present invention relates to coatings comprising polyethylene glycol and at least one polyphenolic polymer. In particular, the polyphenolic polymer could be selected from the group consisting of tyrosine-derived polyarylates, linear polyesteramides, dihydroxybenzoate polymers, and resorcinol-derived polymers. The coating of the present invention may also include a drug, such as an antibiotic. The coatings of the present invention are suitable for use as coatings for medical devices, such as orthopedic pins or stents.

Novel absorbable polymer blends are disclosed. The blends are useful for manufacturing medical devices having engineered degradation and breaking strength retention in vivo. The blends consist of a first absorbable polymeric component and a second absorbable polymeric component. The weight average molecular weight of the first polymeric component is higher than the weight average molecular weight of the second polymeric component. At least at least one of said components is at least partially end-capped by a carboxylic acid group. Further aspects are medical devices made therefrom.

Medical device are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is water-soluble. In further embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has a molecular weight of from 80 to 750 or has more than four hydroxyl groups.

A method and apparatus are disclosed for forming a drug coating layer capable of preventing breakage of elongated drug crystals on a surface of a balloon and maintaining the drug crystals in an appropriate shape in order to act on a living body. The method includes supplying a coating solution which contains the water-insoluble drug, a water-soluble additive, an organic solvent, and water to the surface of the balloon and evaporating the organic solvent and the water to form an additive layer containing the water-soluble additive and a protruding crystal having a tip end protruding from the additive layer, cutting a surplus portion protruding from the additive layer of the protruding crystal from a part surrounded by the additive layer and forming the part surrounded by the additive layer as the elongated body, and removing the cut-out surplus portion from the drug coating layer.

The present disclosure belongs to the technical field of hemostatic materials, and specifically relates to a degradable hemostatic sponge and a preparation method and use thereof, and a degradable drug-loaded hemostatic sponge. The degradable hemostatic sponge provided by the present disclosure is prepared from raw materials including a crosslinking-modified starch and a cellulose through freeze-drying, where a mass ratio of the crosslinking-modified starch to the cellulose is (0.2-5):1. The degradable hemostatic sponge provided by the present disclosure has a high water-absorbing rate and a large water-absorbing capacity, shows a high support strength and a long support time after water absorption, and is made from plant-derived raw materials and thus may be completely biodegraded. The degradable drug-loaded starch hemostatic sponge provided by the present disclosure has a drug-loaded coating attached to a surface of the sponge, where the drug is slowly released while a support is maintained.

An isolated peptide is disclosed. The peptide comprises a titanium oxide binding amino acid sequence connected to a heterologous biologically active amino acid sequence via a beta sheet breaker linker, wherein: (i) the titanium oxide binding amino acid sequence is selected to bind coordinatively with titanium oxide; (ii) the titanium oxide binding amino acid sequence is selected to induce a beta sheet structure; and (ii) the titanium oxide binding amino acid sequence binds to titanium oxide with a higher affinity than said biologically active amino acid sequence binds to the titanium oxide under physiological conditions. Use of the peptides and titanium devices comprising same are also disclosed.

Various embodiments of the present invention include a cannula coated or compounded with a material to extend the wear time for a patient by reducing inflammation and therefore increasing the time that the cannula may remain inserted, thereby increasing the effectiveness of the drug delivered using the cannula. The material may include a hydrophilic material, an anti-microbial material, an anti-inflammatory material, anti-thrombogenic material, or a combination of any of these materials.

Disclosed is a medical device constructed and arranged for contact with a flow of blood or other bodily fluid of a patient and including an attached binding agent or a roughened surface that binds to pathogenic cells targeted for elimination from the blood or other bodily fluid. Also disclosed are methods for making and using the device.

The present invention relates to a coating comprising at least one biodegradable polymer, wherein the polymer comprises at least one or a blend of a poly (ester amide) (PEA) having a chemical formula described by structural formula (II), wherein; R.sub.1 is independently selected from the group consisting of (C.sub.2-C.sub.20)alkylene, (C.sub.2-C.sub.20)alkenylene, —(R.sub.9—CO—O—R.sub.10—O—CO—R.sub.9)—, CH R.sub.11—O—CO—R.sub.12—COOCR.sub.11— and combinations thereof; R.sub.3 and R.sub.4 in a single co-monomer m or p, respectively, are independently selected from the group consisting of hydrogen, (C.sub.1-C.sub.6)alkyl, (C.sub.2-C.sub.6)alkenyl, (C.sub.2-C.sub.6)alkynyl, (C.sub.6-C.sub.10)aryl, (C.sub.1C.sub.6)alkyl, —(CH.sub.2)SH, —(CH.sub.2).sub.2S(CH.sub.3), CH.sub.2OH, —CH(OH)CH.sub.3, —(CH.sub.2).sub.4NH.sub.3+, ˜(CH.sub.2).sub.3NHC(═NH.sub.2+)NH.sub.2, —CH.sub.2COOH, (CH.sub.2)COOH, —CH.sub.2—CO—NH.sub.2—CH.sub.2CH.sub.2—CO—NH.sub.2, —CH.sub.2CH.sub.2COOH, CH.sub.3—CH.sub.2—CH(CH.sub.3)—, formula (a), HO-.sub.P-Ph-CH.sub.2—, (CH.sub.3).sub.2—CH—, Ph- NH—, NH—(CH.sub.2).sub.3—C—, NH—CH═N—CH═C—CH.sub.2—. R.sub.5 or R.sub.6 are independently selected from bicyclic-fragments of 1,4:3,6-dianhydrohexitols or from the group consisting of (C.sub.2-C.sub.20)alkylene, (C.sub.2-C.sub.20)alkenylene, alkyloxy, oligoethyleneglycol with a Mw ranging from 44 Da up to 700 Da, —CH.sub.2—CH—(CH.sub.2OH).sub.2, CH.sub.2CH(OH)CH.sub.2 whereby R.sub.5 and R.sub.6 are non identical. R.sub.7 is hydrogen, (C.sub.6-C.sub.10) aryl, (C.sub.1C.sub.6) alkyl or a protecting group such as benzyl- or a bioactive agent; R.sub.8 is independently (C.sub.1-C.sub.20) alkyl or (C.sub.2-C.sub.20)alkenyl; R.sub.9 or R.sub.10 are independently selected from C.sub.2-C.sub.12 alkylene or C.sub.2-C.sub.12 alkenylene and R.sub.11 or R.sub.12 are independently selected from H, methyl, C.sub.2-C.sub.12 alkylene or C.sub.2-C.sub.12 alkenylene.

##STR00001##